Stockreport

Context Therapeutics CEO Teases Q2 Claudin 6 Data, Nectin-4 Clinic Entry at TD Cowen Conference [Yahoo! Finance]

Context Therapeutics Inc.  (CNTX) 
PDF and plans to enter the clinic with Nectin-4 (CT-202) the same quarter, while mesothelin (CT-95) data are targeted for mid-2026 to create an "almost quarterly" update cad [Read more]